What's happened
Researchers at Northwestern University have identified when and where toxic proteins build up in the brain, and found that the drug levetiracetam, sold as Keppra, can prevent this process. The drug may delay Alzheimer’s progression if administered early, with ongoing studies exploring its preventative potential.
What's behind the headline?
The discovery that levetiracetam can prevent amyloid-beta 42 formation shifts the focus from treatment to prevention of Alzheimer’s. This approach could revolutionize early intervention, especially for high-risk groups like those with genetic predispositions or Down syndrome. The fact that the drug is already approved accelerates potential clinical application, but its rapid breakdown in the body remains a challenge. Developing longer-lasting formulations will be crucial for effective preventative use. The research underscores the importance of early detection, possibly decades before symptoms appear, to maximize benefits. If successful, this could significantly delay or even prevent the onset of dementia, transforming the landscape of neurodegenerative disease management.
What the papers say
The NY Post reports that Northwestern University scientists identified the timing and location of toxic protein accumulation in Alzheimer’s, with levetiracetam preventing amyloid-beta 42 formation. The Independent highlights that targeting the HOXD13 protein in melanoma reveals new immune evasion mechanisms, but also notes ongoing trials for drugs that could enhance immune response. The same publication discusses a separate study where inhibiting PTP1B, an insulin-regulating protein, cleared amyloid plaques in mice, offering another promising avenue. While these studies differ in focus—Alzheimer’s versus melanoma—they collectively demonstrate a broader trend: repurposing existing drugs and targeting specific proteins can open new pathways for treating complex diseases. The common thread is early intervention and the potential to slow or halt disease progression before irreversible damage occurs.
How we got here
Alzheimer’s disease is characterized by the buildup of toxic proteins, notably amyloid-beta 42, which form plaques in the brain. Current treatments mainly focus on clearing existing plaques, but recent research aims to prevent their formation. Northwestern University’s team discovered that amyloid-beta 42 accumulates inside synaptic vesicles, and that levetiracetam can inhibit this process. The drug is already approved for seizures, making it a promising candidate for repurposing in Alzheimer’s prevention. The research builds on understanding how aging weakens the brain’s ability to divert proteins from harmful pathways, leading to neurodegeneration.
Go deeper
More on these topics